Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 37

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 37
---
’s Form S-4 Registration Statement relating to the Kineta Merger) in order to increase the number of authorized
shares of Common Stock.

3.3 . Except as set forth in this Agreement or as disclosed in the SEC Reports, the
Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company’s presently outstanding securities or any of its securities that may hereafter be issued, other than such
rights and obligations that have expired or been satisfied or waived.

3.4 . The Company has all requisite corporate
power and authority to enter into the Transaction Agreements and to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the shares of Common Stock
issuable upon exercise of the Warrants (the “Warrant Shares”). All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Shares and Warrant Shares, the
authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Securities and the Warrant Shares, has been taken. This Agreement
has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by each Investor and that this Agreement constitutes the legal, valid and binding agreement of each Investor, this Agreement and each of
the Securities constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and
similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).

6

3.5 . The Shares being purchased by Investors hereunder have been duly
and validly authorized and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and
non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal
securities laws), and the holder of the Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the approval of the Authorized Share Increase Proposal (as defined in